Compositions and methods for treating macrophage activation syndrome
By using IMH001, an antibody specific for human GM-CSF protein, the problem of high toxicity of existing HLH/MAS treatment methods is solved, and the effect of delaying disease progression and improving symptoms is achieved.
Patent Information
- Application Number
- CN202380030616.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-30
- Filing Date
- 2023-12-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-12-28
AI Technical Summary
Existing HLH/MAS treatments rely on steroids such as dexamethasone, which are toxic and increase mortality, and patients need safer treatments.
An antibody or fragment thereof specific to the human GM-CSF protein, such as IMH001, is used to delay disease progression by administration to a patient.
Effectively delayed the disease progression of HLH/MAS, improved hemocytogenes, ferritin levels and inflammation indicators, and reduced hemophagocytic action and lymphocyte depletion.
Smart Images

Figure CN119095618A_ABST
Abstract
Description
Background Art
[0001] Hemophagocytic lymphohistiocytosis (HLH) is a fatal autosomal recessive disease that manifests in early childhood. The disease is characterized by fever, hepatosplenomegaly, cytopenias, and extensive infiltration of vital organs by activated lymphocytes and macrophages. Macrophage activation syndrome (MAS), also known as secondary HLH, is a rare and severe life-threatening disease. MAS is considered to be a hyperinflammatory 'cytokine storm' state associated with rheumatic disease or other predisposing factors. The exact mechanism of MAS is unclear. However, regardless of the initiating events of these diseases, the final condition is defined by overactive immunity leading to chronic inflammation and hemophagocytic action. MAS is characterized by fever, hyperferritinemia, hemophagocytosis, cytopenias (including pancytopenia), and hepatosplenomegaly.
[0002] Current treatments for HLH / MAS rely on various immunosuppressive regimens with dexamethasone or other steroids, cyclosporine, and etoposide. These therapies are inherently toxic and increase mortality in patients with established disease. Therefore, newer, safer therapies are greatly needed for patients with HLH / MAS. Summary of the invention
[0003] The present disclosure provides compositions and methods for treating and preventing hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS). The method involves administering an antibody or fragment thereof specific for human GM-CSF protein, such as IMH001, to a patient in need thereof. Treatment using the anti-GM-CSF antibodies provided herein has shown effective efficacy in delaying disease progression.
[0004] One embodiment of the present disclosure provides a method for treating or preventing macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) in a patient in need thereof, the method comprising administering to the patient an antibody or fragment thereof specific for human GM-CSF protein.
[0005] One embodiment of the present disclosure provides antibodies or fragments thereof specific for human GM-CSF protein for use in treating or preventing macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) in a patient in need thereof.
[0006] One embodiment of the present disclosure provides the use of an antibody or fragment thereof specific for human GM-CSF protein in the preparation of a medicament for treating or preventing macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) in a patient in need thereof.
[0007] In some embodiments, the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the antibody comprises human IgG1 Fc.
[0008] In some embodiments, the patient has a disease or condition selected from the group consisting of systemic-onset juvenile idiopathic arthritis (SoJIA), systemic lupus erythematosus (SLE), Kawasaki disease, and adult-onset Still's disease.
[0009] In some embodiments, the patient has a blood ferritin level of at least 300 ng / ml, or at least 350 ng / ml, 400 ng / ml, 450 ng / ml, 500 ng / ml, 550 ng / ml, 600 ng / ml, 650 ng / ml, 684 ng / ml, 700 ng / ml, 720 ng / ml, 740 ng / ml, 750 ng / ml, 760 ng / ml, 784 ng / ml, 800 ng / ml, 820 ng / ml, 840 ng / ml, 850 ng / ml, 860 ng / ml, 884 ng / ml, 900 ng / ml, 950 ng / ml, or 1000 ng / ml.
[0010] In some embodiments, the patient has a hemoglobin level of less than 11 g / dL, or less than 10.5 g / dL, 10 g / dL, 9.5 g / dL, 9 g / dL, 8.5 g / dL, 8 g / dL, 7.5 g / dL, or 7 g / dL.
[0011] In some embodiments, the patient has a platelet count of less than 140×10 9 / L, or less than 130×10 9 / L, 120×10 9 / L, 110×10 9 / L, 100×10 9 / L, 90×10 9 / L, 80×10 9 / L, 70×10 9 / L or 60×10 9 / L.
[0012] In some embodiments, the patient has a neutrophil count of less than 1.4×10 9 / L, or less than 1.3×10 9 / L, 1.2×10 9 / L, 1.1×10 9 / L, 1.0×10 9 / L, 0.9×10 9 / L, 0.8×10 9 / L, 0.7×10 9 / L or 0.6×10 9 / L.
[0013] In some embodiments, the patient has a fasting triglyceride level of above 2.49 mmol / L, or above 2.55 mmol / L, 2.6 mmol / L, 2.66 mmol / L, 2.72 mmol / L, 2.77 mmol / L, 2.83 mmol / L, 2.89 mmol / L, 2.94 mmol / L, 3 mmol / L, 3.06 mmol / L, 3.11 mmol / L, 3.17 mmol / L, 3.23 mmol / L, 3.28 mmol / L, 3.34 mmol / L, or 3.4 mmol / L.
[0014] In some embodiments, the patient has a blood fibrinogen level of less than 1.5 g / L, or less than 1.4 g / L, 1.3 g / L, 1.2 g / L, 1.1 g / L, 1.0 g / L, 0.9 g / L, 0.8 g / L, 0.7 g / L, 0.6 g / L, or 0.5 g / L.
[0015] In some embodiments, the patient has elevated soluble CD163 levels compared to healthy individuals. In some embodiments, the patient has elevated soluble IL-2 receptor levels compared to healthy individuals.
[0016] In some embodiments, the antibody or its antigen-binding fragment is administered at 0.3 mg / kg to 10 mg / kg. In some embodiments, the antibody or its antigen-binding fragment is administered once a week, once every two weeks, or once a month. In some embodiments, the antibody or its antigen-binding fragment is administered intravenously or subcutaneously.
[0017] In some embodiments, the antibody is provided in a formulation comprising: 20 mg / ml-200 mg / ml of antibody; 10 mM-30 mM of a buffer; 130 mM-250 mM of an isotonicity regulator; and 0.01% (w / v)-0.03% (w / v) of a surfactant, wherein the formulation has a pH of 4.5-7.5.
[0018] In some embodiments, the formulation comprises 50-150 mg / ml of antibody, 10-20 mM histidine, 200-220 mM sucrose, and 0.01-0.03% (w / v) polysorbate 80 at a pH of about 5.5-6.1.
[0019] In some embodiments, the formulation comprises about 100 mg / ml of antibody, about 20 mM histidine, about 220 mM sucrose, and about 0.02% (w / v) polysorbate 80 at a pH of about 5.8.
[0020] In some embodiments, the method further comprises administering a glucocorticoid, cyclosporine or anakinra to the subject. In some embodiments, the glucocorticoid is selected from the group consisting of: cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, deflazacort, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone and beclometasone. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Body weight changes of treatment groups are shown.
[0022] Figure 2 Shown are changes in RBC (Panel A), HGB (Panel B), NEUT% (Panel C), MONO% (Panel D) of the treatment groups.
[0023] Figure 3 Shown are changes in total bone marrow viable cells among treatment groups.
[0024] Figure 4 Levels of fibrinogen (Panel A), triglycerides (Panel B), and ferritin (Panel C) are shown for the treatment groups.
[0025] Figure 5 Histopathological evaluation of hemophagocytosis (Panel A), inflammatory infiltrate (Panel B), and lymphocyte depletion (Panel C) of the treatment groups are shown. DETAILED DESCRIPTION
[0026] Before describing the present disclosure in detail, it should be understood that the present disclosure is not limited to the specific compositions or biological systems described, which may of course vary. It should also be understood that the terms used herein are for the purpose of illustrating specific embodiments only and are not intended to be limiting. As used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, a reference to a "molecule" optionally includes a combination of two or more such molecules, etc.
[0027] As used herein, the term "about" refers to the usual error range of the corresponding value that is readily known to those skilled in the art. References herein to "about" values or parameters include (and describe) embodiments involving the value or parameter itself. In the event of doubt or there is no common understanding in the art regarding the error range of a value or parameter, "about" means ± 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of the value or parameter.
[0028] It should be understood that the aspects and embodiments of the present disclosure described herein include "comprising the aspects and embodiments," "consisting of the aspects and embodiments," and "consisting essentially of the aspects and embodiments."
[0029] As used herein, the term "antibody" is generally intended to refer to immunoglobulin molecules comprising four polypeptide chains (two heavy (H) chains and two light (L) chains interconnected by disulfide bonds) and multimers thereof (e.g., IgM); however, immunoglobulin molecules consisting only of heavy chains (i.e., lacking light chains) are also encompassed within the definition of the term "antibody". Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from amino-terminus to carboxyl-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0030] Unless otherwise specifically stated, as used herein, the term "antibody" should be understood to cover intact antibody molecules as well as antigen-binding fragments thereof. As used herein, the term "antigen-binding portion" or "antigen-binding fragment" of an antibody (or simply "antibody portion" or "antibody fragment") refers to one or more fragments of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc., which retain the ability to specifically bind to human GM-CSF or an epitope thereof.
[0031] The term "specific binding" and the like means that the antibody or its antigen-binding fragment forms a relatively stable complex with the antigen under physiological conditions. Specific binding can be achieved by at least about 1×10 -8 The method for determining whether two molecules specifically bind is known in the art and includes, for example, equilibrium dialysis, surface plasmon resonance, and the like. However, an isolated antibody that specifically binds to human GM-CSF may have cross-reactivity with other antigens, such as GM-CSF from other species (orthologs). In the context of the present disclosure, a multispecific (e.g., bispecific) antibody that binds to human GM-CSF and one or more additional antigens is considered to "specifically bind" to human GM-CSF. Moreover, the isolated antibody may be substantially free of other cellular material or chemicals.
[0032] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient to be effective, and that contains no other components that are unacceptably toxic to a subject to which the formulation is administered. Such formulations are sterile.
[0033] As used herein, the term "treat" or "treatment" refers to both therapeutic treatment and prophylactic or preventive measures, wherein the purpose is to prevent or slow down (mitigate) the progression of a physiological change or disorder, such as cancer. Beneficial or desired clinical results include, but are not limited to, relieving symptoms, reducing the extent of the disease, stabilizing (i.e., not worsening) the disease state, delaying or slowing the progression of the disease, improving or alleviating the disease state, and alleviating (whether partially or completely), whether detectable or undetectable. "Treatment" may also refer to extending survival compared to the expected survival when not receiving treatment. Those in need of treatment include those who already have a condition or disorder and those who are susceptible to a condition or disorder or those in which the condition or disorder is to be prevented.
[0034] As used herein, the terms "prevention" or "prophylaxis" refer to the preventive or protective treatment of a disease or disease state. Prevention of a disease or disease state can include reducing (e.g., alleviating) one or more symptoms of the disease or disease state, for example, relative to a reference level (e.g., symptoms of a similar subject not administered with treatment). Prevention can also include delaying the onset of one or more symptoms of a disease or disease state, for example, relative to a reference level (e.g., the onset of one or more symptoms in a similar subject not administered with treatment). In an embodiment, the disease is a disease described herein.
[0035] "Subject" or "individual" or "animal" or "patient" or "mammal" means any subject, particularly a mammalian subject, for whom diagnosis, prognosis or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals and zoo animals, competition animals or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, etc. Treatment of macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH)
[0036] The inventors of the present invention tested the anti-GM-CSF antibody IMH001 in an animal model for macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH). MAS animals are immunodeficient and express human GM-CSF and IL-3 cytokines. Animals exhibit progressive disease with many features of MAS and rapidly develop progressive anemia and weight loss.
[0037] When treated with IMH001, animals showed reduced weight loss (or even weight gain), improved anemia (improved red blood cell count, hemoglobin, and hematocrit), and inhibition of ferritin increase compared to controls. Thus, such in vivo data demonstrate the efficacy of IMH001 in treating MAS or HLH.
[0038] Therefore, according to one embodiment of the present technology, a method for treating or preventing macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) is provided. In some embodiments, the method involves administering an anti-GM-CSF antibody or antigen-binding fragment to a patient in need thereof. As used herein, the term "GM-CSF" means human granulocyte macrophage colony stimulating factor. GM-CSF, also known as colony stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that acts as a cytokine. Naturally occurring drug analogs of GM-CSF are also known as sargramostim and molgramostim. Antibodies against human GM-CSF are described, for example, in WO 2006122797, WO 2015028657 and WO2018050111.
[0039] In some embodiments, the anti-GM-CSF antibody is IMH001, which is a humanized IgG1 antibody comprising a heavy chain variable region (VH) of SEQ ID NO:1 and a light chain variable region (VL) of SEQ ID NO:2.
[0040] In some embodiments, the patient has MAS or HLH. In some embodiments, the patient is at risk for MAS or HLH. In some embodiments, the HLH / MAS patient or a patient at risk for HLH / MAS has a disease or condition such as systemic onset juvenile idiopathic arthritis (SoJIA), systemic lupus erythematosus (SLE), Kawasaki disease, or adult-onset Still's disease.
[0041] "Systemic juvenile idiopathic arthritis (SoJIA)" (or the juvenile-onset form of Still's disease) is a type of juvenile idiopathic arthritis (JIA) that, in addition to arthritis, has extra-articular manifestations such as fever and rash. It was originally called systemic juvenile rheumatoid arthritis or Still's disease. The main manifestations are extra-articular manifestations, such as high fever, rheumatic rash, hepatosplenomegaly, lymphadenopathy, and anemia. Other manifestations include inflammation of the pleura, inflammation of the pericardium, inflammation of the cardiac musculature, and inflammation of the peritoneum may also be seen.
[0042] Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms can be mild or severe and vary from person to person. Common symptoms include joint pain and swelling, fever, chest pain, hair loss, mouth sores, swollen lymph nodes, feeling tired, and a red rash, most often on the face. There are usually periods of disease activity called flares and periods of remission when symptoms are few.
[0043] Kawasaki disease is a syndrome of unknown cause that causes fever and mainly affects children under 5 years of age. It is a form of vasculitis, in which blood vessels throughout the body become inflamed. The fever usually lasts for more than five days and is not responded to common medicines. Other common symptoms include enlarged lymph nodes in the neck, a rash in the genital area, lips, palms, or soles of the feet, and red eyes. Within three weeks of the onset of the disease, the skin on the hands and feet may peel off, after which it usually recovers. In some children, coronary artery aneurysms form in the heart.
[0044] Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease characterized by the classic triad of fever, joint pain, and a prominent salmon-colored bumpy rash. The disease is considered a diagnosis of exclusion. Levels of the iron-binding protein ferritin may increase dramatically in this condition.
[0045] In some embodiments, the patient has abnormally high blood ferritin levels. In some embodiments, the blood ferritin level is at least 300 ng / ml, or at least 350 ng / ml, 400 ng / ml, 450 ng / ml, 500 ng / ml, 550 ng / ml, 600 ng / ml, 650 ng / ml, 684 ng / ml, 700 ng / ml, 720 ng / ml, 740 ng / ml, 750 ng / ml, 760 ng / ml, 784 ng / ml, 800 ng / ml, 820 ng / ml, 840 ng / ml, 850 ng / ml, 860 ng / ml, 884 ng / ml, 900 ng / ml, 950 ng / ml, or 1000 ng / ml.
[0046] In some embodiments, administration of an anti-GM-CSF antibody provided herein reduces blood ferritin levels by at least 10%, at least 20%, at least 30%, at least 50%, or at least 70% compared to an untreated control. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally high blood ferritin levels in a patient.
[0047] In some embodiments, the patient has abnormally low hemoglobin levels. In some embodiments, the hemoglobin level is less than 11 g / dL, or less than 10.5 g / dL, 10 g / dL, 9.5 g / dL, 9 g / dL, 8.5 g / dL, 8 g / dL, 7.5 g / dL, or 7 g / dL.
[0048] In some embodiments, administration of an anti-GM-CSF antibody provided herein increases blood hemoglobin levels by at least 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 fold compared to an untreated control. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally low hemoglobin levels in a patient.
[0049] In some embodiments, the patient has an abnormally low platelet count. In some embodiments, the platelet count is less than 140×10 9 / L, or less than 130×10 9 / L, 120×10 9 / L, 110×10 9 / L, 100×10 9 / L, 90×10 9 / L, 80×10 9 / L, 70×10 9 / L or 60×10 9 / L.
[0050] In some embodiments, administration of an anti-GM-CSF antibody provided herein increases platelet count by at least 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 fold compared to an untreated control. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally low platelet counts in a patient.
[0051] In some embodiments, the patient has an abnormally low neutrophil count. In some embodiments, the neutrophil count is less than 1.4×10 9 / L, or less than 1.3×10 9 / L, 1.2×10 9 / L, 1.1×10 9 / L, 1.0×10 9 / L, 0.9×10 9 / L, 0.8×10 9 / L, 0.7×10 9 / L or 0.6×10 9 / L.
[0052] In some embodiments, administration of an anti-GM-CSF antibody provided herein increases neutrophil counts by at least 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 fold compared to an untreated control. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally low neutrophil counts in a patient.
[0053] In some embodiments, the patient has abnormally high fasting triglyceride levels. In some embodiments, the fasting triglyceride level is higher than 2.49mmol / L, or higher than 2.55mmol / L, 2.6mmol / L, 2.66mmol / L, 2.72mmol / L, 2.77mmol / L, 2.83mmol / L, 2.89mmol / L, 2.94mmol / L, 3mmol / L, 3.06mmol / L, 3.11mmol / L, 3.17mmol / L, 3.23mmol / L, 3.28mmol / L, 3.34mmol / L or 3.4mmol / L. In some embodiments, the fasting triglyceride level is above 220 mg / dl, or above 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, or 300 mg / dl.
[0054] In some embodiments, administration of an anti-GM-CSF antibody provided herein reduces fasting triglyceride levels by at least 10%, at least 20%, at least 30%, at least 50%, or at least 70% compared to an untreated control. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally high fasting triglyceride levels in a patient.
[0055] In some embodiments, the patient has abnormally low blood fibrinogen levels. In some embodiments, the blood fibrinogen level is less than 1.5 g / L, or less than 1.4 g / L, 1.3 g / L, 1.2 g / L, 1.1 g / L, 1.0 g / L, 0.9 g / L, 0.8 g / L, 0.7 g / L, 0.6 g / L or 0.5 g / L.
[0056] In some embodiments, administration of an anti-GM-CSF antibody provided herein increases blood fibrinogen levels by at least 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8 fold. In some embodiments, administration of an anti-GM-CSF antibody provided herein reverses abnormally low blood fibrinogen levels in a patient.
[0057] In some embodiments, administration of an anti-GM-CSF antibody provided herein reduces or reverses high hemophagocytosis levels in a patient.
[0058] In some embodiments, administration of an anti-GM-CSF antibody provided herein reduces or reverses high inflammatory infiltrate levels in a patient.
[0059] In some embodiments, administration of an anti-GM-CSF antibody provided herein reduces or reverses high lymphocyte depletion in a patient.
[0060] In some embodiments, administration of an anti-GM-CSF antibody provided herein increases viable bone marrow cells.
[0061] In some embodiments, the patient has macrophage activation. In some embodiments, the patient has elevated soluble CD163 levels compared to healthy individuals. In some embodiments, the patient has lymphocyte activation. In some embodiments, the patient has elevated soluble IL-2 receptor levels compared to healthy individuals.
[0062] In some embodiments, the patient meets two or more of the above criteria. In some embodiments, the patient meets three, four, five or more of the above criteria.
[0063] The amount of the antibody of the present disclosure that is effective in treatment. The precise dose to be used in the formulation will also depend on the route of administration and the severity of the disease, disorder or condition, and should be determined according to the physician's judgment and each patient's circumstances. The effective dose can be inferred from dose-response curves derived from in vitro or animal model test systems.
[0064] As a general suggestion, the dosage of the antigen-binding polypeptides of the present disclosure administered to the patient is generally 0.1 mg / kg to 100 mg / kg patient weight, between 0.1 mg / kg and 20 mg / kg patient weight, or between 1 mg / kg and 10 mg / kg patient weight. In general, due to the immune response to exogenous polypeptides, the half-life of human antibodies in the human body is longer than the half-life of antibodies from other species. Therefore, the dosage of human antibodies can usually be reduced and the frequency of administration can be reduced. In addition, the dosage and frequency of administration of the antibodies of the present disclosure can be reduced by modifying (e.g., lipidation) to enhance the uptake and tissue penetration (e.g., into the brain) of the antibodies.
[0065] In some embodiments, the dosage of IMH001 is 0.1 to 25 mg / kg, 0.3 to 20 mg / kg, 0.3 to 15 mg / kg, 0.3 to 10 mg / kg, 0.5 to 20 mg / kg, 1 to 20 mg / kg, 5 to 20 mg / kg, 6 to 20 mg / kg, 6 to 10 mg / kg, 5 to 10 mg / kg per administration. In some embodiments, the dosage is at least 0.3 mg / kg, or at least 0.6 mg / kg, 1 mg / kg, 1.3 mg / kg, 1.6 mg / kg, 2 mg / kg, 2.3 mg / kg, 2.6 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg or 10 mg / kg. In some embodiments, the dosage is no more than 15 mg / kg, 14 mg / kg, 13 mg / kg, 12 mg / kg, 11 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg or 2 mg / kg. In some embodiments, the administered dosage is 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 12 mg / kg, 15 mg / kg, 20 mg / kg or 25 mg / kg.
[0066] In some embodiments, administration is once a day, once every 2 days, once every 3 days, once every 4 days, once a week, twice a week, once every two weeks, once every three weeks, once a month, or once every two months.
[0067] Methods for administering antibodies include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. Antibodies or compositions can be administered by any convenient route, such as by infusion or bolus injection, absorbed by epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered with other bioactive agents. Therefore, pharmaceutical compositions containing antibodies of the present disclosure can be administered orally, rectally, parenterally, intracistemal, intravaginally, intraperitoneally, topically (e.g., by powders, ointments, drops, or transdermal patches), buccally, or as an oral or nasal spray.
[0068] As used herein, the term "parenteral" refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, and intraarticular injection and infusion.
[0069] Administration may be systemic or local. In addition, it is desirable to introduce the antibodies of the present disclosure into the central nervous system by any suitable route, including intraventricular injection and intrathecal injection; intraventricular injection may be facilitated, for example, by a ventricular catheter attached to a reservoir (such as an Ommaya reservoir). Pulmonary administration may also be employed, for example, by using an inhaler or nebulizer, and formulations with an atomizing agent.
[0070] It is desirable to administer the antibodies or compositions of the present disclosure locally to the area in need of treatment; this can be achieved, for example but not limited to, by local infusion during surgery, topical application (e.g., in conjunction with a wound dressing after surgery), by injection, by catheter, by suppository, or by implant, which is a porous, non-porous or gelatinous material, including membranes, such as sialastic membranes or fibers. Preferably, when administering the proteins (including antibodies) of the present disclosure, care must be taken to use materials that the proteins do not absorb.
[0071] In another embodiment, the antibody or composition can be delivered in a vesicle, particularly a liposome (see Langer, 1990, Science 249: 1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, supra, pp. 317-327; see generally supra)
[0072] In yet another embodiment, the antibody or composition can be delivered in a controlled release system. In one embodiment, a pump can be used (see Sefton, 1987, CRC Crit. Ref. Biomed. Eng. [CRC Biomedical Engineering Critical Review] 14:201; Buchwald et al., 1980, Surgery [Surgery] 88:507; Saudek et al., 1989, N. Engl. J. Med. [New England Journal of Medicine] 321:574). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, FL (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., 1983, Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed near the therapeutic target (i.e., the brain), thus requiring only a fraction of the systemic dose (see, e.g., Good Son, in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138 (1984)). Other controlled release systems are discussed in the review by Langer (1990, Science 249: 1527-1533). Combinations and preparations
[0073] In some embodiments, the patient may be further administered a second agent. Non-limiting examples of second agents include glucocorticoids, cyclosporine, and anakinra.
[0074] Examples of glucocorticoids include Cortisol (hydrocortisone), cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, deflazacort, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, and beclomethasone.
[0075] The formulated antibodies are preferably substantially pure, and desirably substantially homogeneous (e.g., free of contaminating proteins, etc.). By "substantially pure" antibody is meant a composition comprising at least about 90% by weight of the antibody, preferably a composition comprising at least about 95% by weight of the antibody, based on the total weight of protein in the composition, and by "substantially homogeneous" antibody is meant a composition comprising at least about 99% by weight of the antibody, based on the total weight of protein in the composition.
[0076] The term "pharmaceutical formulation" refers to a preparation containing an anti-GM-CSF antibody in a form that permits the biological activity of the active ingredient to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.
[0077] The formulations may be liquid or aqueous.Liquid formulations are aqueous solutions or suspensions prepared in a suitable aqueous solvent such as water or an aqueous / organic mixture such as a hydroalcoholic mixture.
[0078] In certain embodiments, the liquid drug formulation comprises 20 mg / ml-200 mg / ml of antibody, e.g., 30 mg / ml-200 mg / ml, 40 mg / ml-200 mg / ml, 50 mg / ml-200 mg / ml, 60 mg / ml-200 mg / ml, 70 mg / ml-200 mg / ml, 80 mg / ml-200 mg / ml, 90 mg / ml-200 mg / ml, 100 mg / ml-200 mg / ml, 110 mg / ml-200 mg / ml, 200mg / ml, 120mg / ml-200mg / ml, 130mg / ml-200mg / ml, 140mg / ml-200mg / ml, 150mg / ml-200mg / ml, 160mg / ml-20 0mg / ml, 170mg / ml-200mg / ml, 180mg / ml-200mg / ml, 190mg / ml-200mg / ml, 20mg / ml-190mg / ml, 20mg / ml-180mg / ml l, 20mg / ml-170mg / ml, 20mg / ml-160mg / ml, 20mg / ml-150mg / ml, 20mg / ml-140mg / ml, 20mg / ml-130mg / ml, 20mg / ml-120mg / ml, 20mg / ml-110mg / ml, 20mg / ml-100mg / ml, 20mg / ml-90mg / ml, 20mg / ml-80mg / ml, 20mg / ml-70mg / ml , 20mg / ml-60mg / ml, 20mg / ml-50mg / ml, 20mg / ml-40mg / ml, 30mg / ml-190mg / ml, 40mg / ml-180mg / ml, 50mg / ml-17 0mg / ml, 60mg / ml-160mg / ml, 70mg / ml-150mg / ml, 80mg / ml-140mg / ml, 90mg / ml-130mg / ml, 100mg / ml-120mg / ml. In certain embodiments, the liquid drug formulation comprises 20 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 110 mg / ml, 120 mg / ml, 130 mg / ml, 140 mg / ml, 150 mg / ml, 160 mg / ml, 170 mg / ml, 180 mg / ml, 190 mg / ml, or 200 mg / ml of antibody.
[0079] In another embodiment, the pharmaceutical formulation further comprises an additional excipient. The term "excipient" as used herein refers to an inert substance commonly used as a diluent, vehicle, preservative, binder or stabilizer for a drug that imparts beneficial physical properties to the formulation, such as increasing protein stability, increasing protein solubility and reducing viscosity.
[0080] "Excipients" include, but are not limited to: stabilizers, such as human serum albumin (HSA), bovine serum albumin (BSA), α-casein, globulin, α-lactalbumin, LDH, lysozyme, myoglobin, ovalbumin, RNase A; buffers, such as citric acid, HEPES, PBS, histidine, potassium acetate, potassium citrate, potassium phosphate (KH2PO4), sodium acetate, sodium bicarbonate, sodium citrate, sodium phosphate (NaH2PO4), Tris base and Tris-HCl; amino acids / metabolites, such as glycine, alanine (α-alanine, β-alanine), arginine, betaine, leucine, lysine, glutamic acid, aspartic acid, histidine, proline, 4-hydroxyproline, sarcosine, γ-aminobutyric acid (GABA), opines (alanopine, octopine, strombine) and trimethylamine N-oxide (TMAO); surfactants, such as polysorbate 60, ester 20 and polysorbate 80 and poloxamer 407; lipid molecules such as phosphatidylcholine, ethanolamine and acetyltryptophan ester; polymers such as polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) 10, 24, 40; low molecular weight excipients such as arabinose, cellobiose, ethylene glycol, fructose, fucose, galactose, glycerol / glycerol, glucose, inositol, lactose, maltose, maltotriose, mannose, melibiose, 2-methyl-2,4-pentanediol , octulose, propylene glycol, raffinose, ribose, sucrose, trehalose, xylitol and xylose; and high molecular weight excipients such as cellulose, β-cyclodextrin, dextran (10 kd), dextran (40 kd), dextran (70 kd), polysucrose, gelatin, hydroxypropyl methylcellulose, hydroxyethyl starch, maltodextrin, methylcellulose, PEG (6 kd), polydextrose, polyvinylpyrrolidone (PVP) k15 (10 kd), PVP (40 kd), PVP k30 (40 kd), PVP k90 (1000 kd), dextran gel G-200 and starch; antioxidants such as ascorbic acid, cysteine hydrochloride, monothioglycerol, thioglycolic acid, thiosorbitol and glutathione; reducing agents such as cysteine hydrochloride, dithiothreitol and other thiols or thiophenes; chelating agents such as EDTA, EGTA, glutamic acid and aspartic acid; inorganic salts / metals such as Ca 2 +、Ni 2 +、Mg 2 +、Mn 2+, Na2SO4, (NH4)2SO4, Na2HPO4 / NaH2PO4, K2HPO4 / KH2PO4, MgSO4 and NaF; organic salts such as sodium acetate, sodium polyvinyl, sodium caprylate / Na octanoate, proprionate, lactate, succinate and citrate; organic solvents such as acetonitrile, dimethyl sulfoxide (DMSO) and ethanol. For additional information on excipients, see Remington's Pharmaceutical Sciences (Joseph P. Remington, 18th ed., Mack Publishing Co., Easton, Pa.), which is incorporated herein in its entirety.
[0081] "Iso-osmotic" means that the target preparation has the osmotic pressure substantially the same as human blood. Isotonic preparations generally have an osmotic pressure of about 250 to about 350mOsm (e.g., about 250 to about 340, about 250 to about 330, about 250 to about 320, about 250 to about 310, about 250 to about 300, about 260 to about 350, about 270 to about 350, about 280 to about 350, about 290 to about 350, about 300 to about 350, about 260 to about 340, about 270 to about 330, about 280 to about 320, about 290 to about 310mOsm). Isotonic pressure can be measured using, for example, vapor pressure or a freezing type osmometer. In certain embodiments, isotonic pressure is about 300mOsm. Isotonic pressure regulators can be one or more selected from the group consisting of: sucrose, trehalose, mannitol, arginine and sodium chloride. In certain embodiments, the range of isotonicity adjusting agents is about 130-250 mM (e.g., about 130 mM to about 240 mM, about 150 mM to about 240 mM, about 180 mM to about 240 mM, about 200 mM to about 240 mM, about 130 mM to about 220 mM, about 150 mM to about 220 mM, about 180 mM to about 220 mM, about 130 mM to about 210 mM, about 150 mM to about 210 mM, about 180 mM to about 210 mM, about 200 mM to about 220 mM, or about 200 to about 210 mM). In some embodiments, the isotonicity adjusting agent is about 130mM, about 140mM, about 150mM, about 160mM, about 170mM, about 180mM, about 190mM, about 200mM, about 210mM, about 220mM, about 230mM, about 240mM or about 250mM. In certain embodiments, the isotonicity adjusting agent comprises sucrose or trehalose.
[0082] As used herein, "pH buffer" refers to a buffered solution that resists pH changes through the action of its acid-base conjugate components. Preferably, the buffer of the present disclosure has a pH in the range of about 4.5 to about 7.5 (preferably about 5.0 to about 7.0, such as about 5.0 to about 6.9, about 5.2 to about 6.8, about 5.3 to about 6.7, about 5.4 to about 6.6, about 5.5 to about 6.5, about 5.6 to about 6.4, about 5.7 to about 6.3, about 5.8 to about 6.2, about 5.9 to about 6.1, about 5.5 to about 6.4, about 5.5 to about 6.3, about 5.5 to about 6.2, about 5.5 to about 6.1 or about 5.5 to about 6.0). In some embodiments, the buffer has a pH of about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, or 7.0. In one embodiment, the buffer has a pH of 5.8. The desired pH level can be achieved by a variety of methods, including but not limited to the addition of a suitable buffer.
[0083] In certain embodiments, the pH buffer comprises histidine, acetate, citrate, and succinate. In certain embodiments, the pH buffer comprises about 10 to about 30 mM histidine and / or about 10 to about 30 mM acetate, such as about 10 to about 25 mM, about 10 to about 20 mM, or about 15 mM to about 20 mM histidine and / or about 10 to about 25 mM, about 10 mM to about 20 mM, or about 15 mM to about 20 mM acetate. In some embodiments, the pH buffer comprises about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM histidine or acetate.
[0084] In certain embodiments, the pH buffer comprises L-histidine and histidine hydrochloride monohydrate. In certain embodiments, the pH buffer comprises 20 mM histidine, the histidine comprises about 4.4 mM L-histidine and about 15.6 mM histidine hydrochloride monohydrate, about 5.2 mM L-histidine and about 14.8 mM histidine hydrochloride monohydrate, about 6.2 mM L-histidine and about 13.8 mM histidine hydrochloride monohydrate, about 6.8 mM L-histidine and about 13.2 mM histidine hydrochloride monohydrate, about 7.8 mM L-histidine and about 12.2 mM histidine hydrochloride monohydrate, about 8.4 mM L-histidine hydrochloride monohydrate and about 11.6 mM histidine hydrochloride monohydrate, or about 9 mM L-histidine and about 11 mM histidine hydrochloride monohydrate.
[0085] As used herein, "surfactant" refers to an agent having surface activity, preferably a nonionic surfactant. Examples of surfactants herein include polysorbates (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, and polysorbate 85); Poloxamers (e.g., poloxamer 188 and poloxamer 407); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside (sodium octyl sulfate); glycoside); lauryl-sultaine, myristyl-sultaine, linoleyl-sultaine or stearyl-sultaine; lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine or stearyl-sarcosine; linoleyl-betaine, myristyl-betaine or cetyl-betaine; lauramidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmitamidopropyl-betaine or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristamidopropyl-dimethylamine, palmitamidopropyl-dimethylamine or isostearamidopropyl-dimethylamine; sodium methyl cocoyl taurate or disodium methyl oleyl taurate; and MONAQUAT TM series (Mona Industries, Inc., Paterson, NJ); polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Piuronics, PF68, etc.); and the like.
[0086] Surfactant concentration is typically about 0.0001% (w / v) to about 1.0% (w / v), about 0.01% (w / v) to about 0.5% (w / v), for example, about 0.015% (w / v) to about 0.03% (w / v), about 0.02% (w / v) to about 0.03% (w / v), about 0.025% (w / v) to about 0.03% (w / v), about 0.01% (w / v) to about 0.025% (w / v), about 0.01% (w / v) to about 0.02% (w / v) or about 0.01% (w / v) to about 0.015% (w / v). In one embodiment, the surfactant provided herein comprises polysorbate 80 or polysorbate 20. In certain embodiments, the surfactant comprises about 0.01% (w / v), 0.015% (w / v), 0.02% (w / v), 0.025% (w / v), or 0.03% (w / v) polysorbate 80 or polysorbate 20. In certain embodiments, the surfactant comprises about 0.02% (w / v) polysorbate 80.
[0087] In certain embodiments, the liquid pharmaceutical formulation further comprises an antioxidant, a preservative, or a mixture thereof.
[0088] The term "antioxidant" refers to an agent that inhibits oxidation of other molecules. Examples of antioxidants include ascorbic acid, citrate, lipoic acid, uric acid, cysteine hydrochloride, monothioglycerol, thioglycerol, thioglycolic acid, thiosorbitol, tocopherol, carotene, lycopene, and glutathione; reducing agents such as cysteine hydrochloride, dithiothreitol, phosphonate compounds such as etidronic acid, deferoxamine, and malate, and other thiols or thiophenes and methionine. In other embodiments, the antioxidant is a metal chelator. Metal chelators include, but are not limited to, ethylenediaminetetraacetate ("EDTA"), ethylene glycol tetraacetic acid ("EGTA"), tetrahydrofuranmethyldithiothiamine ("TTFD"), and 2,3-dimercaptosuccinic acid ("DMSA"). In certain embodiments, the formulation comprises about 1 mM to about 50 mM antioxidant. In one embodiment, the formulation comprises about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, or about 45 mM antioxidant.
[0089] The term "preservative" refers to a pharmaceutically acceptable excipient that prevents the growth of microorganisms within the composition. More particularly, the present disclosure provides a multi-dose liquid composition containing a preservative that protects the composition from microbial contamination.
[0090] In one embodiment, the preservative is present in the composition in an amount of 0.001% (w / v) to 2% (w / v). In one embodiment, the preservative is present in the composition in an amount of 0.002% (w / v) to 1% (w / v). In one embodiment, the one or more preservatives are selected from phenol, meta-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, para-chloro-meta-cresol, methylparaben, propylparaben, benzalkonium chloride, thimerosal or any combination thereof. In one embodiment, the one or more preservatives are selected from phenol, meta-cresol, benzyl alcohol and chlorobutanol.
[0091] The viscosity of the anti-GM-CSF antibody formulation can be controlled for subcutaneous, intravenous, or intramuscular administration. Viscosity can be affected by protein concentration and pH. For example, as protein concentration increases, viscosity can increase. Increasing pH can reduce the viscosity of the anti-GM-CSF antibody formulation. In some protein formulations, sodium chloride is added to reduce the viscosity of the formulation. Other components that can affect the viscosity of the anti-GM-CSF antibody formulation are amino acids, such as histidine and arginine.
[0092] The liquid drug formulations described herein can have various viscosities. Methods for measuring the viscosity of liquid drug formulations are known to those skilled in the art, and may include, for example, a rheometer (e.g., Anton Paar MCR301 Rheometer with 50mm, 40mm or 20mm cone accessories). In some embodiments of the present disclosure, viscosity is reported at a high shear limit of 1000 / sec shear rate. In some embodiments, the liquid drug formulation has a viscosity between 1.0cP ± 10% and 20cP ± 10%. In some embodiments, the liquid drug formulation has a viscosity of less than 20cP, less than 18cP, less than 15cP, less than 13cP or less than 11cP. It will be understood by those skilled in the art that viscosity depends on temperature, and therefore, unless otherwise stated, the viscosity provided herein is measured at 25°C, unless otherwise stated. In some embodiments, the viscosity of the liquid drug formulation at 25° C. is 1.0 cP ± 10%, 2.0 cP ± 10%, 3.0 cP ± 10%, 3.1 cP ± 10%, 3.2 cP ± 10%, 3.5 cP ± 10%, 3.6 cP ± 10%, 3.8 cP ± 10%, 4.0 cP ± 10%, 5.0 cP ± 10%, 5.3 cP ± 10%, 6.0 cP ± 10%, 6.3 cP ± 10%, ±10%, 6.4cP±10%, 6.8cP±10%, 7.0cP±10%, 7.1cP±10%, 7.4cP±10%, 8.0cP±10%, 9.0cP±10%, 10.0cP±10%, 11.0cP±10%, 12.0cP±10%, 13.0cP±10%, 14.0cP±10%, 15.0cP±10% or 16cP±10%.
[0093] In certain embodiments, the liquid drug formulation further comprises a viscosity modifier. In one embodiment, the viscosity modifier is an amino acid. In one embodiment, the viscosity modifier is L-proline. In certain embodiments, the concentration of the viscosity modifier is 1% ± 0.2% to 5% ± 1% w / v. In one embodiment, the viscosity modifier is proline at a concentration of 1.5% ± 0.3% or about 1.5%. In one embodiment, the viscosity modifier is proline at a concentration of 3% ± 0.6% or about 3%.
[0094] In a first aspect, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) an anti-GM-CSF antibody at a concentration of 20 mg / ml-200 mg / ml as an antibody; b) acetate or histidine at a concentration of 10 mM to 30 mM as a buffer; c) sucrose or trehalose at a concentration of 130 mM to 250 mM as an isotonicity regulator; d) polysorbate 80 or polysorbate 20 at a concentration of 0.01% (w / v) to 0.03% (w / v) as a surfactant; The pH of the formulation is from about 4.5 to about 7.5, preferably from about 5.5 to about 6.1.
[0095] In a further embodiment, the formulation comprises no other excipients.
[0096] In a preferred embodiment, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) anti-GM-CSF antibody at a concentration of 50 mg / ml-150 mg / ml; b) histidine at a concentration of 10 mM to 20 mM; c) sucrose at a concentration of 200 mM-220 mM; d) polysorbate 80 at a concentration of 0.01% (w / v) to 0.03% (w / v); Wherein the formulation has a pH of 5.5 to 6.1.
[0097] In a further embodiment, the formulation comprises no other excipients.
[0098] In a more preferred embodiment, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) an anti-GM-CSF antibody at a concentration of 100 mg / ml, wherein the anti-GM-CSF antibody comprises a heavy chain variable region CDR1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, a light chain variable region CDR1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6; b) histidine at a concentration of 20 mM; c) sucrose at a concentration of 220 mM; d) polysorbate 80 at a concentration of 0.02% (w / v); The formulation had a pH of 5.8.
[0099] In a further embodiment, the formulation comprises no other excipients.
[0100] The pharmaceutical formulation can be administered to the patient by a parenteral route such as injection (e.g., subcutaneous, intravenous, intramuscular, intraperitoneal, etc.) or transdermal, mucosal, nasal, pulmonary or oral administration. Many reusable pen or automatic syringe delivery devices can be used for subcutaneous delivery of the pharmaceutical formulation of the present disclosure. Examples include, but are not limited to: AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONIC TM Pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25 TM Pen, HUMALOG TM Pen, HUMALIN 70 / 30 TM PEN (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN TM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR TM (Novo Nordisk, Copenhagen, Denmark), BD TM PEN (BD Company (BectonDickinson), Franklin Lakes, New Jersey), OPTIPEN TM 、OPTIPEN PRO TM , OPTIPEN STARLET TM and OPTICLIK TM (sanofi-aventis, Frankfurt, Germany). Examples of disposable pen or auto-injector delivery devices for subcutaneous delivery of the pharmaceutical compositions of the present disclosure include, but are not limited to: SOLOSTAR TM Pen (Sanofi-Aventis), FLEXPEN TM (Novo Nordisk) and KWIKPEN TM (Eli Lilly), SURECLICK TM Autoinjector (Amgen, Thousand Oaks, Calif.), PENLET TM (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA TM Pen (Abbott Labs, Abbott Park, Ill.).
[0101] It is also contemplated herein to use a microinfusion device to deliver the pharmaceutical formulations disclosed herein. As used herein, the term "microinfusion device" means a subcutaneous delivery device designed to slowly administer a large volume (e.g., up to about 2.5 mL or more) of a therapeutic formulation over an extended period of time (e.g., about 10, 15, 20, 25, 30 or more minutes). See, e.g., U.S. Patent No. 6,629,949; U.S. Patent No. 6,659,982; and Meehan et al., J. Controlled Release [Journal of Controlled Release] 46: 107-116 (1996). Microinfusion devices are particularly suitable for delivering large doses of therapeutic proteins contained in high concentrations (e.g., about 100, 125, 150, 175, 200 mg / mL or higher) or viscous solutions.
[0102] In certain embodiments, the present disclosure provides a prefilled syringe comprising any one of the liquid formulations described herein. In certain embodiments, the syringe is a 1 mL or 2.25 mL long glass syringe filled with a 27-gauge thin-walled needle, a fluorocarbon-coated rubber plunger, and a rubber needle shield.
[0103] In one aspect, the liquid pharmaceutical formulations of the disclosure can be stored at room temperature, refrigerated (eg, 2-8°C), or frozen (eg, -20°C or -70°C).
[0104] In certain embodiments, the formulation of any of the foregoing aspects has a property selected from the group consisting of: (i) the formulation is stable for long-term storage at 50°C, 40°C, 25°C, 5°C, -20°C, -30°C, and -80°C; (ii) the formulation has low viscosity (viscosity less than 10 cP); (iv) the formulation is isotonic to physiological conditions; (v) the formulation is stable and compatible with intravenous or subcutaneous delivery devices and procedures; and (vi) the formulation is stable for long-term storage in a glass vial or prefilled syringe.
[0105] On the one hand, the preparation retains its physical and chemical stability and its biological activity substantially during storage. The shelf life is usually selected based on the expected shelf life of the preparation. A variety of analytical techniques for measuring protein stability are available in the art and are reviewed in, for example, Peptide and Protein Drug Delivery, 247-301, Vincent Lee, Marcel Dekker, Inc., New York, NY, published (1991) and Jones, A. Adv. Drug Delivery Rev., 10: 29-90 (1993). Stability can be measured at a selected temperature in a selected time period. For example, a liquid preparation is stable at about 40°C for at least about 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks. In another aspect, the liquid formulation is stable at about 5°C and / or 25°C for at least about 1 month, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, or at least about 36 months; and / or at about -20°C and / or -70°C for at least about 1 month, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 42 months, or at least about 48 months. In addition, in some embodiments, the liquid formulation can be stable after being frozen (to, e.g., -80°C) and thawed (e.g., after 1, 2, or 3 freeze and thaw cycles).
[0106] The stability of liquid formulations can be qualitatively and / or quantitatively assessed in a variety of different ways, including assessment of dimer, multimer and / or aggregate formation (e.g., using size exclusion chromatography (SEC), matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), analytical ultracentrifugation, light scattering (photon correlation spectroscopy, dynamic light scattering (DLS), static light scattering, multi-angle laser light scattering (MALLS)), flow-based microscopic imaging (flow-based microscopy), and / or quantitative analysis of the formation of dimers, multimers, and / or aggregates. imaging), electrical impedance (Coulter) counting, light obscuration or other liquid particle counting systems, by measuring turbidity and / or by visual inspection); assessing charge heterogeneity by using cation exchange chromatography (CEX), isoelectric focusing (IEF) (e.g., capillary technology (cIEF)), or capillary zone electrophoresis; amino-terminal or carboxyl-terminal sequence analysis; mass spectrometry analysis; SDS-PAGE or SEC analysis to compare fragmented, intact and multimeric (i.e., dimer, trimer, etc.) antibodies; peptide mapping (e.g., trypsin or LYS-C) analysis; evaluating the biological activity or antigen binding function of the antibody; and the like. The stability of the formulation in the solid state can also be qualitatively and / or quantitatively evaluated in a variety of different ways, including direct tests such as identification of crystal structure by X-ray powder diffraction (XRPD); evaluation of antibody structure in the solid state using Fourier transform infrared spectroscopy (FTIR); and measurement of thermal transitions (melting, glass transition, etc.) in lyophilized solids using differential scanning calorimetry (DSC) and indirect tests (such as measurement of moisture content by Karl Fisher test), for example, to infer the possibility of chemical instability caused by hydrolysis. Instability can involve any one or more of the following: aggregation (e.g., non-covalent soluble aggregation, covalent soluble aggregation (e.g., disulfide bond rearrangement / disorder), insoluble aggregation), deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), shearing / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, N-terminal extension, C-terminal processing, glycosylation differences, etc. Examples Example 1. IMH001 inhibits the development of MAS and improves symptoms
[0107] This study was conducted to evaluate the in vivo efficacy of the GM-CSF neutralizing antibody IMH001 (see sequence in Table 1) in delaying disease progression in the NOG-EXL mouse macrophage activation syndrome (MAS) model induced by CBMC transplantation. This lymphocyte-independent effector-driven MAS mouse model can be established by transplanting human umbilical cord blood (UCB) into NOG-EXL mice. scid IL tm1Sug Tg(SV40 / HTLV-IL3,CSF2) is based on NOG(NOD.Cg-Prkdc scid IL tm1Sug A genetically modified strain of NOG-EXL mice that is immunodeficient and constitutively overexpresses human IL-3 and GM-CSF, which can enrich myeloid cell populations, including DCs, monocytes, and macrophages, after human stem cell transplantation. A total of 46 NOG-EXL mice and 8 NOG mice were used in this study. Table 1. VH / VL sequences of IMH001
[0108] This model displays a progressive disease with many features of MAS and rapidly develops progressive anemia without the need for exogenous immune stimulation. Therefore, this model can be used to examine the contribution of the monocyte / macrophage arm and identify new therapeutic strategies for MAS / HLH. 1.1 Methods
[0109] Five to six-week-old NOG-EXL mice were irradiated with 1 Gy prior to reconstitution with OKT3-pretreated cord blood mononuclear cells (CBMCs) by tail vein injection. The day of reconstitution was defined as day 0. OKT3-pretreated CBMC-transplanted NOG-EXL mice were treated with biweekly ip doses of PBS or 10 mg / kg IMH001 starting from week 1 of implantation. Animal body weight, CBC counts, and serum ferritin were measured at the indicated time points.
[0110] One week after reconstitution (day 7), four NOG mice (G1) and 14 NOG-EXL mice (6 G2 mice and 8 G3 mice, respectively) were administered twice a week for 15 weeks. The grouping and dosing schedule are shown in Table 2 below: Table 2. Grouping and dosing regimen
[0111] Body weight: After CBMC transplantation, the body weight of mice was measured and recorded once a week.
[0112] CBC counts: Whole blood was collected from mice and counted by a CBC machine at weeks 4, 8, and 16. Total bone marrow viable cells were also counted at the end of the study, week 16. Before blood collection, mice were anesthetized with 3%-4% isoflurane.
[0113] Cytokines measured by MSD method: Serum was collected for the determination of IL-1β, IL-6, TNF-α, GM-CSF, IFN-γ, and IL-12 at weeks 8 and 10. Before blood collection, mice were anesthetized with 3%-4% isoflurane.
[0114] Ferritin, fibrinogen, and triglycerides: Serum was collected from mice at weeks 8 and 16. The measurements were then performed individually using ELISA kits. Prior to blood collection, mice were anesthetized with 3%-4% isoflurane.
[0115] Experimental endpoint collection: The endpoint was day 112 / week 16. Spleens were collected from all mice in each group and weighed; cell smears from bone marrow, liver, and spleen sections were collected for Wright Giemsa staining to detect the presence of hemophagocytosis. Activated lymphoid tissue, spleen / lymph nodes, liver, and meninges were collected for H&E sections to detect inflammatory cell infiltration in spleen / lymph nodes and a reduction in lymphoid follicles.
[0116] statistics
[0117] All statistical analysis methods involved in this project must be consistent with the experimental plan, and the results are expressed as mean ± SEM. First, use the F test (IDBS E-WorkBook 10.5.0 (64bit) The variance was analyzed by IDBS. If the variance was homogeneous (p>0.05), one-way ANOVA was performed. T test was used for comparison between two groups, and Dunnett's multiple comparison method was used for comparison between multiple groups. If the variance was heteroscedastic (p≤0.05), the Kruskal-Wallis method was used for nonparametric test, the U test was used for comparison between two groups (Kruskal-Wallis parametric test had significant difference, p≤0.05), and the Dunn's multiple comparison method was used for comparison between multiple groups (Kruskal-Wallis parametric test had no significant difference, p>0.05). p<0.05 was considered to be significantly different. 1.2 Results
[0118] Soon after OKT3-pretreated CBMCs were transplanted into NOG-EXL mice, the mice developed MAS, characterized by weight loss, a gradual decrease in red blood cell (RBC) count, hemoglobin (HGB), and hematocrit (HCT), and high ferritin. 1.2.1 Weight changes
[0119] However, treatment with IMH001 completely reversed disease progression. Following CBMC engraftment, animals were weighed weekly.
[0120] No obvious abnormalities were found in any group during the experiment. Figure 1 The weight changes at each time point in each group are shown in . As the disease progresses, sustained weight loss is observed in NOG or NOG-EXL mice transplanted with CBMCs. Compared with the vehicle control group (G2), the body weight of the IMH001 treatment group (G3: 10 mg / kg) increased significantly from day 63 to day 112 (p<0.05). This result shows that IMH001 treatment effectively improves the weight loss of animals caused by MAS. 1.2.2 Peripheral blood and bone marrow cell counts
[0121] Whole blood was collected from mice and complete blood count (CBC) analysis was performed at weeks 4, 8, 12, and 16. Total bone marrow viable cells were also counted at the end of the study (week 16). Figure 2 RBC, HGB, NEUT, MONO at each time point in each group are shown in the figure. As the disease progressed, a continuous decrease in the number of peripheral RBCs, HGB levels, and NEUT percentage was observed in NOG-EXL:CBMC-transplanted mice, and there was no significant change in the number of PLTs and the percentage of MONO. After IMH001 treatment, recovery of the reduction in RBC and NEUT was observed, especially on day 56, when the cell number and HGB level of RBC were significantly higher compared with those without treatment (6.45 vs. 8.17, p<0.001). The percentage of monocytes in the IMH001-treated group was also reduced, which is considered to be a pharmacological effect of IMH001.
[0122] Figure 3 Total bone marrow viable cells are shown in Figure 1. There was a trend of an increase in total bone marrow cells on day 112 compared to mice not treated with NOG-EXL (mean 9.55 vs. 11.6, p=0.182). The number of peripheral RBCs continued to decrease in the MAS control group. Treatment with IMH001 can effectively improve the number of RBCs in peripheral blood, accompanied by an increase in HGB. 1.2.3 Ferritin, fibrinogen and triglycerides
[0123] Serum was collected from mice at 8 and 16 weeks. Figure 4Ferritin, fibrinogen, and triglycerides at each time point in each group are shown in Figure 2. In NOG-EXL CBMC-transplanted mice, ferritin, one of the indicators of macrophage activation, increased significantly with disease progression, while this phenomenon was not observed in NOG CBMC-transplanted mice. Moreover, IMH001 treatment effectively controlled ferritin levels compared with no treatment, which was observed at weeks 8 and 16. No significant changes in fibrinogen and triglycerides were observed during disease progression and after IMH001 treatment.
[0124] The results showed that the peripheral blood ferritin level in the MAS control group was significantly increased, indicating the activation of macrophages. Treatment with IMH001 significantly reduced the level of peripheral blood ferritin. 1.2.4 Histopathological evaluation
[0125] At the end of the study (week 16), cytological smears from bone marrow, liver, and spleen sections were collected for Wright-Giemsa staining to detect the presence of hemophagocytosis. Activated lymphoid tissue / lymph nodes and spleen were collected for H&E staining to evaluate lymphocyte depletion; H&E staining was performed on the liver and brain / meninges to detect inflammatory cell infiltration. Figure 5 The results are shown in .
[0126] Hemophagocytosis: Macrophages containing hemosiderin were seen in the splenic red pulp sections and bone marrow smears of the MAS control group, indicating hemophagocytosis. IMH001 treatment effectively prevented MAS-associated hemophagocytosis.
[0127] Lymphocyte depletion: The number of lymphoid follicles and germinal centers in the spleen and the number of lymphocytes in the lymph nodes of NOG-EXL mice were reduced, indicating lymphocyte depletion. IMH001 treatment effectively reduced lymphocyte depletion. In addition, reduced inflammatory infiltration was observed in the liver and meninges after IMH001 treatment.
[0128] Results showed that 16 weeks after CBMC transplantation, NOG-EXL mice showed increased hemophagocytosis, lymphocyte depletion, and elevated inflammation compared with NOG mice. These histopathological parameters were significantly improved in IMH001-treated mice.
[0129] Hemophagocytosis: Macrophages containing hemosiderin were seen in the red pulp sections of the spleen and bone marrow smears of the MAS control group, indicating hemophagocytosis.
[0130] Lymphocyte depletion: The numbers of lymphoid follicles and germinal centers in the spleen and the number of lymphocytes in the lymph nodes were reduced in NOG-EXL mice, indicating lymphocyte depletion.
[0131] The study showed that IMH001 treatment demonstrated efficacy in delaying disease progression in all of the above parameters compared to tocilizumab. Example 2. Development of IMH001 formulation
[0132] This example develops a suitable formulation for the clinical use of IMH001 in the treatment of MAS.
[0133] First, three different buffer systems were evaluated at various pH levels for IMH001: sodium acetate, histidine hydrochloride, and sodium dihydrogen phosphate. All three buffer systems were able to stabilize the antibody, and pH 5.5 to 6.0 seemed more beneficial than 6.5 or higher. Histidine hydrochloride and pH 5.8 were selected for further testing.
[0134] Next, multiple excipients were evaluated, including sucrose, trehalose, mannitol, proline, arginine hydrochloride, glycine, sodium chloride, PS20, and PS80. Formulations with different excipients were compared based on changes in stability (CEX-HPLC) results at 50°C for 1 week. Results showed that sucrose and proline were similar in performance and slightly better than the other formulations. Sucrose was selected for further development.
[0135] However, it was unclear whether the selected buffer and excipients would render the protein solubility of IMH001 suitable for subcutaneous injection at high concentrations. Therefore, the solubility and viscosity of the protein at concentrations of 100 mg / ml and 150 mg / ml in a histidine hydrochloride buffer system (pH 5.8) were evaluated.
[0136] In a 20 mmol / L histidine hydrochloride buffer system (pH 5.8), when the protein concentration was 100 mg / ml and 150 mg / ml and the samples were placed at 4°C and 25°C for 48 hours, there was no significant change in the appearance color, clarity, OD350, protein concentration and viscosity, among which the viscosity was less than 10 cP and the clarity was less than 6 NTU.
[0137] The ability of PS80 (polysorbate 80) to improve the durability and stability of candidate formulations at different concentrations of sucrose for a protein concentration of 100 mg / ml was then tested. The viscosity of all samples was acceptable and the viscosity decreased as the sucrose concentration decreased.
[0138] After further adjusting the concentration of each component, the following formulation was determined to be superior to the other candidate formulations: 100 mg / ml IMH001, 20 mM histidine, 220 mM sucrose, and 0.02% (w / v) polysorbate 80, pH 5.8. This formulation was used as the stock solution for the following in vivo studies. ***
[0139] The scope of the present disclosure is not limited by the particular embodiments described, which are intended to be a single illustration of the various aspects of the present disclosure, and any compositions or methods that are functionally equivalent are within the scope of the present disclosure. It will be apparent to those skilled in the art that various modifications and variations may be made to the methods and compositions of the present disclosure without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure is intended to cover modifications and variations of the present disclosure as long as they are within the scope of the appended claims and their equivalents. All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Claims
1. A method for treating or preventing macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH) in a patient in need thereof, the method comprising administering to the patient an antibody or fragment thereof specific for human GM-CSF protein.
2. The method of claim 1, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
2.
3. The method of claim 2, wherein the antibody comprises human IgG1 Fc.
4. The method of any one of the preceding claims, wherein the patient has a disease or condition selected from the group consisting of systemic onset juvenile idiopathic arthritis (SoJIA), systemic lupus erythematosus (SLE), Kawasaki disease, and adult-onset Still's disease.
5. The method of any one of the preceding claims, wherein the patient has a blood ferritin level of at least 300 ng / ml, or at least 350 ng / ml, 400 ng / ml, 450 ng / ml, 500 ng / ml, 550 ng / ml, 600 ng / ml, 650 ng / ml, 684 ng / ml, 700 ng / ml, 720 ng / ml, 740 ng / ml, 750 ng / ml, 760 ng / ml, 784 ng / ml, 800 ng / ml, 820 ng / ml, 840 ng / ml, 850 ng / ml, 860 ng / ml, 884 ng / ml, 900 ng / ml, 950 ng / ml or 1000 ng / ml.
6. The method of any of the preceding claims, wherein the patient has a hemoglobin level of less than 11 g / dL, or less than 10.5 g / dL, 10 g / dL, 9.5 g / dL, 9 g / dL, 8.5 g / dL, 8 g / dL, 7.5 g / dL or 7 g / dL.
7. The method of any one of the preceding claims, wherein the patient has a platelet count of less than 140×10 9 / L, or less than 130×10 9 / L, 120×10 9 / L, 110×10 9 / L, 100×10 9 / L, 90×10 9 / L, 80×10 9 / L, 70×10 9 / L or 60×10 9 / L.
8. The method of any of the preceding claims, wherein the patient has a neutrophil count of less than 1.4 x 10 9 / L, or less than 1.3×10 9 / L, 1.2×10 9 / L, 1.1×10 9 / L, 1.0×10 9 / L, 0.9×10 9 / L, 0.8×10 9 / L, 0.7×10 9 / L or 0.6×10 9 / L.
9. The method of any of the preceding claims, wherein the patient has a fasting triglyceride level of greater than 2.49 mmol / L, or greater than 2.55 mmol / L, 2.6 mmol / L, 2.66 mmol / L, 2.72 mmol / L, 2.77 mmol / L, 2.83 mmol / L, 2.89 mmol / L, 2.94 mmol / L, 3 mmol / L, 3.06 mmol / L, 3.11 mmol / L, 3.17 mmol / L, 3.23 mmol / L, 3.28 mmol / L, 3.34 mmol / L or 3.4 mmol / L.
10. The method of any of the preceding claims, wherein the patient has a blood fibrinogen level of less than 1.5 g / L, or less than 1.4 g / L, 1.3 g / L, 1.2 g / L, 1.1 g / L, 1.0 g / L, 0.9 g / L, 0.8 g / L, 0.7 g / L, 0.6 g / L or 0.5 g / L.
11. The method of any one of the preceding claims, wherein the patient has elevated levels of soluble CD163 compared to healthy individuals.
12. The method of any one of the preceding claims, wherein the patient has elevated levels of soluble IL-2 receptor compared to healthy individuals.
13. The method of any one of claims 1-12, wherein the antibody or antigen-binding fragment thereof is administered at 0.3 mg / kg to 25 mg / kg.
14. The method of any one of claims 1-12, wherein the antibody or antigen-binding fragment thereof is administered at 5 mg / kg to 20 mg / kg.
15. The method of any one of claims 1-12, wherein the antibody or antigen-binding fragment thereof is administered at 5 mg / kg to 10 mg / kg.
16. The method of any one of claims 1-12, wherein the antibody or antigen-binding fragment thereof is administered at 6 mg / kg to 10 mg / kg.
17. The method of any of the preceding claims, wherein the antibody or antigen-binding fragment thereof is administered once a week, twice a week, once every two weeks, or once a month.
18. The method of any of the preceding claims, wherein the antibody or antigen-binding fragment thereof is administered intravenously or subcutaneously.
19. The method of any one of claims 3 to 18, wherein the antibody is provided in the form of a formulation comprising: (a) 20 mg / ml to 200 mg / ml of the antibody; (b) 10 mM-30 mM buffer; (c) 130 mM to 250 mM of an isotonicity adjusting agent; and (d) 0.01% (w / v) to 0.03% (w / v) of a surfactant, Wherein the formulation has a pH of 4.5-7.
5.
20. The method of claim 19, wherein the formulation comprises 50-150 mg / ml of the antibody, 10-20 mM histidine, 200-220 mM sucrose, and 0.01-0.03% (w / v) polysorbate 80 at a pH of about 5.5-6.
1.
21. The method of claim 20, wherein the formulation comprises about 100 mg / ml of the antibody, about 20 mM histidine, about 220 mM sucrose, and about 0.02% (w / v) polysorbate 80 at a pH of about 5.
8.
22. The method of any of the preceding claims, further comprising administering to the patient a glucocorticoid, cyclosporine, or anakinra.
23. The method of claim 22, wherein the glucocorticoid is selected from the group consisting of: Cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, deflazacort, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, and beclomethasone.
Citation Information
Patent Citations
Micro infusion drug delivery device
US6629949B1
Micro infusion drug delivery device
US6659982B2
Anti-GM-CSF antibodies and uses therefor
WO2006122797A2
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2015028657A1
Anti-GM-CSF antibodies and uses thereof
WO2018050111A1
